acetazolamide has been researched along with Alzheimer Disease in 8 studies
Acetazolamide: One of the CARBONIC ANHYDRASE INHIBITORS that is sometimes effective against absence seizures. It is sometimes useful also as an adjunct in the treatment of tonic-clonic, myoclonic, and atonic seizures, particularly in women whose seizures occur or are exacerbated at specific times in the menstrual cycle. However, its usefulness is transient often because of rapid development of tolerance. Its antiepileptic effect may be due to its inhibitory effect on brain carbonic anhydrase, which leads to an increased transneuronal chloride gradient, increased chloride current, and increased inhibition. (From Smith and Reynard, Textbook of Pharmacology, 1991, p337)
Alzheimer Disease: A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57)
| Excerpt | Relevance | Reference |
|---|---|---|
| " From a review of the literature, the optimal technique employs quantitative 15O-water PET imaging determinations of cerebral blood flow (CBF) and acetazolamide (ACZ) (1 g iv with measurements at 10- to 20-min post-administration) as the vasodilating agent." | 3.72 | Technical issues in the determination of cerebrovascular reserve in elderly subjects using 15O-water PET imaging. ( Boles Ponto, LL; Hichwa, RD; Leonard Watkins, G; Schultz, SK, 2004) |
| "The effects of cerebral amyloid angiopathy (CAA) on the function of cerebral blood vessels were analyzed applying cerebral blood volume (CBV)-based fMRI to transgenic arcA beta mice." | 1.36 | Vascular response to acetazolamide decreases as a function of age in the arcA beta mouse model of cerebral amyloidosis. ( Knobloch, M; Mueggler, T; Nitsch, RM; Princz-Kranz, FL; Rudin, M, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (12.50) | 18.7374 |
| 1990's | 2 (25.00) | 18.2507 |
| 2000's | 3 (37.50) | 29.6817 |
| 2010's | 2 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Uekawa, K | 1 |
| Hasegawa, Y | 1 |
| Senju, S | 1 |
| Nakagata, N | 1 |
| Ma, M | 1 |
| Nakagawa, T | 1 |
| Koibuchi, N | 1 |
| Kim-Mitsuyama, S | 1 |
| Likitjaroen, Y | 1 |
| Suwanwela, NC | 1 |
| Phanthumchinda, K | 1 |
| Princz-Kranz, FL | 1 |
| Mueggler, T | 2 |
| Knobloch, M | 1 |
| Nitsch, RM | 1 |
| Rudin, M | 2 |
| Sturchler-Pierrat, C | 1 |
| Baumann, D | 1 |
| Rausch, M | 1 |
| Staufenbiel, M | 1 |
| Boles Ponto, LL | 1 |
| Schultz, SK | 1 |
| Leonard Watkins, G | 1 |
| Hichwa, RD | 1 |
| Knapp, WH | 1 |
| Dannenberg, C | 1 |
| Marschall, B | 1 |
| Zedlick, D | 1 |
| Löschmann, K | 1 |
| Bettin, S | 1 |
| Barthel, H | 1 |
| Seese, A | 1 |
| Pávics, L | 1 |
| Grünwald, F | 1 |
| Reichmann, K | 1 |
| Horn, R | 1 |
| Kitschenberg, A | 1 |
| Hartmann, A | 1 |
| Menzel, C | 1 |
| Schomburg, AG | 1 |
| Overbeck, B | 1 |
| Csernay, L | 1 |
| Biersack, HJ | 1 |
| Bonte, FJ | 1 |
| Devous, MD | 1 |
| Reisch, JS | 1 |
| Ajmani, AK | 1 |
| Weiner, MF | 1 |
| Hom, J | 1 |
| Tintner, R | 1 |
1 trial available for acetazolamide and Alzheimer Disease
| Article | Year |
|---|---|
Changes in local cerebral blood flow by neuroactivation and vasoactivation in patients with impaired cognitive function.
Topics: Acetazolamide; Aged; Alzheimer Disease; Brain; Cerebrovascular Circulation; Cognition Disorders; Fem | 1996 |
7 other studies available for acetazolamide and Alzheimer Disease
| Article | Year |
|---|---|
Intracerebroventricular Infusion of Angiotensin-(1-7) Ameliorates Cognitive Impairment and Memory Dysfunction in a Mouse Model of Alzheimer's Disease.
Topics: Acetazolamide; Alzheimer Disease; Amyloid beta-Peptides; Angiotensin I; Animals; Avoidance Learning; | 2016 |
Vasoreactivity induced by acetazolamide in patients with vascular dementia versus Alzheimer's disease.
Topics: Acetazolamide; Aged; Aged, 80 and over; Alzheimer Disease; Brain; Cardiovascular Agents; Cerebrovasc | 2009 |
Vascular response to acetazolamide decreases as a function of age in the arcA beta mouse model of cerebral amyloidosis.
Topics: Acetazolamide; Aging; Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Cerebral Amyloid A | 2010 |
Compromised hemodynamic response in amyloid precursor protein transgenic mice.
Topics: Acetazolamide; Age Factors; Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Bicuculline; | 2002 |
Technical issues in the determination of cerebrovascular reserve in elderly subjects using 15O-water PET imaging.
Topics: Acetazolamide; Aged; Aged, 80 and over; Aging; Alzheimer Disease; Attention; Blood Flow Velocity; Br | 2004 |
Regional cerebral blood flow single-photon emission tomography with 99mTc-HMPAO and the acetazolamide test in the evaluation of vascular and Alzheimer's dementia.
Topics: Acetazolamide; Aged; Alzheimer Disease; Brain; Cerebrovascular Circulation; Dementia, Vascular; Diag | 1999 |
The effect of acetazolamide on regional cerebral blood flow in patients with Alzheimer's disease or stroke as measured by single-photon emission computed tomography.
Topics: Acetazolamide; Aged; Aged, 80 and over; Alzheimer Disease; Cerebrovascular Circulation; Cerebrovascu | 1989 |